Searching for Solutions
Pain in the Nation Report
Trust for America's Health (TFAH) has released the 2025 Pain in the Nation Report, which tracks alcohol, drug, and suicide deaths nationally and for population groups. The report shows that deaths due to drug overdose and alcohol are down nationally, but this progress is uneven across population groups and at risk due to cuts to federal health programs and workforce.
Why Medicaid Matters for Children's Mental Health - Blog from Children’s Hospital Association
Visit this blog from the Children’s Hospital Association, explaining how critical Medicaid is for children's access to mental health services. The House-passed reconciliation bill would make financing changes to Medicaid, that are detrimental to children and pediatric care.
Health Advisory on Artificial Intelligence and Adolescent Well-being Released by American Psychological Association (APA)
This advisory delves into the psychological implications of AI on young people, offering critical insights for policymakers, mental health professionals, and technology developers. This resource provides valuable, evidence-based guidance to inform legislative, educational, and care-delivery efforts.
New Buprenorphine for OUD Labels Clarify Higher Doses Appropriate for Some Patients
Suboxone and Zubsolv have modified their labels to clarify that there is no maximum daily dosage. This follows the FDA’s December recommendation that transmucosal buprenorphine product labels be updated to address misperceptions of a daily maximum dose of 16 or 24 milligrams.
Advanced Track Psychotropic Long-Acting Injectable Program
Coming Soon!
Coming Soon!
This award will recognize individual AAPP members who impact change benefiting patient access to care for individuals living with mental illness and/or the profession of psychiatric pharmacy through advocacy with policymakers and/or decision-makers. Advocacy activities under consideration include those with federal and state government as well as other policymaking entities (e.g., regulatory bodies, state boards of pharmacy, agencies, standards bodies, health system administrators, etc.).
The Early Practitioner Award will recognize the efforts of psychiatric pharmacists in the first 5 years of practice or 5 years after completion of post doctoral training. Recipients will have demonstrated commitment to AAPP and its mission to “advance the reach and practice of psychiatric pharmacy and serve as the voice of the specialty.” The recipient serves as a role model for future leaders within AAPP and Psychiatric Pharmacy.
This award will recognize individual AAPP member efforts and accomplishments in increasing patient access to high quality mental health care in exceptional and distinctive ways. This may include activities that increase access to psychiatric pharmacist-led interprofessional care. Examples include reduction and/or mitigation of social determinants of health for people living with mental illness, increased access to novel treatments and/or clinical interventions through research, etc.
The Judith J. Saklad Memorial Award celebrates the life and work of the late Judith J. Saklad. Dr.
Convince Your Supervisor to Support AAPP 2026 Attendance! The merits of the AAPP Annual Meeting are undeniable. Even so, with most organizations having limited travel and education budgets, it may be necessary to show justification when selling your attendance at AAPP 2026.
Shape the Future of AAPP with Your Board Nominee Recommendations
It is that time of year again where AAPP begins the process of nominating leaders for the AAPP Board for the next two years (2026-2028). AAPP is seeking candidates for the board offices of President-Elect and Member-At-Large (2 positions). Active AAPP members are asked to contribute to the shaping of AAPP’s future by nominating individuals to serve in these important leadership positions. Nominations must be submitted no later than June 24 at Noon Central.
Session Spotlight: New Migraine Treatments: Effective Decision-Making with CGRP Receptor Antagonists
Since 2018, eight novel-mechanism calcitonin gene-related peptide (CGRP) antagonists have been FDA-approved for migraine treatment. This session during the 2025 AAPP Summit aims to help psychiatric pharmacists understand the risks, benefits, and treatment strategies for implementing CGRP antagonists in the treatment of migraines. #psychpharmacy #aapp #bcpp
Session Spotlight: Digital Landscape of Childhood: A Comprehensive Look at Social Media, Technology and Mental Health in Pediatric Populations
Social media is a lifeline and a liability for today’s youth. Join us to explore how psychiatric pharmacists can navigate the digital landscape to protect and support young minds. #2025AAPPSummit #psychpharmacy #aapp
Session Spotlight: The Role of Non-Combustible Tobacco Products as Potential Harm Reduction Interventions for People Who Smoke Cigarettes
With the availability of various non-combustible tobacco products such as e-cigarettes, nicotine pouches, and heat-not-burn products, clinicians should understand their potential risks as well as their potential to reduce the use of combustible cigarettes. This session during the 2025 AAPP Summit aims to educate psychiatric pharmacists on the emerging evidence surrounding non-combustible products.
Session Spotlight: Beyond the Script: Exploring Disparities in Psychotropic Prescribing for Serious Mental Illness
There are significant disparities in the diagnosis of bipolar disorder and schizophrenia among different ethnic groups. This session aims to bring awareness and educate psychiatric pharmacists to better ensure individuals receive evidence-based care for serious mental illness, regardless of their racial or ethnic background. Join us! #psychpharm #2025AAPPSummit #bcpp #aapp